Multiple Sclerosis-related Uveitis: Does MS Treatment Affect Uveitis Course?. (4th May 2017)

• Record Type: Journal Article
• Authors: Jouve, Léa; Benrabah, Rabah; Héron, Emmanuel; Bodaghi, Bahram; Le Hoang, Phuc; Touitou, Valérie
• Is Part Of: Ocular immunology and inflammation. Volume 25:Number 3(2017)
• Page Start: 302
• Page End: 307
• Publication Date: 2017-05-04
• Subjects: Corticosteroids -- cystoid macular edema -- immunosuppressive drugs -- interferon-beta -- relapsing-remitting MS -- uveitis; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.3109/09273948.2015.1125508
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Purpose : Few data are available regarding the optimal treatment of multiple sclerosis (MS)-related uveitis. The aim of this study was to describe clinical features of MS-associated uveitis and determine how MS treatment affects the course of uveitis. Methods : Retrospective, multicenter study. Patients were divided into two groups according to the use (group 2) or not (group 1) of immunomodulatory drugs. Characteristics of uveitis and treatment were reviewed. Results : A total of 68 eyes from 36 patients (17 in group 1 and 19 in group 2) were included. All patients were treated with topical and/or systemic steroids for uveitis. Uveitis occurred 1–17 years prior to neurologic symptoms in 78% of patients. Uveitis was more severe in group 2 ( p <0.05), with a tendency toward a higher rate of chronic uveitis ( p = 0.06). Conclusions : MS-related uveitis has often a favorable evolution. Patients on interferon-beta have more severe and chronic uveitis. As far as we are concerned, interferon-beta given on the sole indication of uveitis is not recommended. If steroid-sparing agent is required for intraocular inflammation, immunosuppressive drugs should be considered.